An Introduction to Bacterial Efflux Pump Inhibitor (EPI) and Analytical Methods for Studying Efflux Pump Inhibitors for Drug Development

Sejyoti Chakraborty  
Biotechnology  
Kalinga Institute of Industrial Technology  
Bhubaneshwar, India  

Ishanee Mazumder  
Biotechnology  
Kalinga Institute of Industrial Technology  
Bhubaneshwar, India  

Chandrashish Roy  
Biotechnology  
Kalinga Institute of Industrial Technology  
Bhubaneshwar, India  

Shibam Dey  
Biotechnology  
Kalinga Institute of Industrial Technology  
Bhubaneshwar, India  

Abstract: - Bacterial diseases are becoming a more severe problem around the world. Treatment of multidrug-resistant pathogens has become a major concern in the present world. Bacterial efflux pumps are present in all microorganisms and play a key role in both innate and acquired bacterial drug resistance. Therefore, discovering small molecule efflux pump inhibitors (EPIs) that are capable of restoring antibiotic effectiveness is a hot topic in the scientific world. Seeking new EPIs has taken a lot of effort over the past two decades. None of them, however, has yet to be approved for medicinal use. To introduce these inhibitors for escalating the responsiveness of bacterial pathogens to antibiotics, we should have proper knowledge of drug detection and the mechanism of efflux pumps. This review of EPIs is a good place to start looking for new anti-bacterial drugs that are safe.

Keywords: - Efflux Mechanisms, Efflux Pump Inhibitor (EPI), Antibiotic Resistance, Multidrug Resistant (MDR), Bacteria.

INTRODUCTION

Antibiotic Resistance can be described as the impotence of the antibiotics to reach the target in adequate concentration for impeding the activity of the target. The reason behind the acquiring resistance is due to: decrease in the affinity of the target for the antibiotic, or, reducing the concentration of the antibiotic in the cell. Bacteria may be intrinsically immune to antibiotics due to systemic or functional differences. Weak permeability of the bacterial cell wall and constitutive expression of efflux pumps are examples of these characteristics that are encoded by house-keeping genes in the bacterial genome [1].

The most common form of resistance factor, efflux pumps, can be found in all species, from bacteria to mammals [2,3]. The function of the efflux pump is to extrude out drugs and chemicals outside the cell wall. The majority of bacterial efflux systems are non-drug-specific proteins that can identify and pump out a wide variety of chemically and structurally unrelated compounds in an energy-dependent manner [4]. Presence of these multidrug efflux mechanisms in pathogenic bacteria has become a major reason for the discovery of the efflux pump inhibitors (EPIs) that helps in blocking the efflux pumps.

MECHANISM OF THE ACTIVITY OF EFFLUX PUMP INHIBITORS (EPIS)

The most promising method for inhibiting multidrug efflux pumps is to use Efflux pump inhibitors (EPIs). This can be accomplished by interacting with the functional assemblies of efflux pump components, and efflux inhibition can help prevent bacterial pathogens from developing resistance. In reality, EPIs function in a variety of ways, depending on their properties and mechanisms, can interfere with efflux function, assembly, and pumping. However, due to the decline in antibiotic expansion, it is important to look for and classify compounds that restore the antibacterial activity of older antibiotics. The efflux pump inhibitor-antibiotic combination is intended to increase the intracellular concentration of antibiotics expelled by efflux pumps, minimize intrinsic bacterial resistance to antibiotics, reverse acquired resistance associated with efflux pump overexpression, and reduce the frequency of resistant mutant strains.

Figure 1: Schematic representation of a tripartite drug efflux complex in complex with a small protein such as AcrZ [5].
Figure 1 shows the action of EPI on a tripartite drug efflux complex, which contain three proteins which span the inner membrane (CM), the outer membrane (OM), and the periplasmic space [5]. The inner-membrane protein (IMP), e.g., AcrB or MexB is responsible for substrate specificity and catalyzes APh dependent drug transport [5]. Examples of the outer membrane protein (OMP) are TolC or OprM [5]. The periplasmic membrane fusion protein (MFP), e.g., AcrA or MexA connects the IMP and the OMP [5].

**EPI Against Gram Positive Bacteria**

Gram-positive bacteria are one of the most common human pathogens linked to clinical infections ranging from minor skin infections to sepsis. Gram-positive bacteria (such as those belonging to the genera Staphylococcus, Streptococcus, and Enterococcus) are among the most common causes of clinical infection. Although the problem of multi-drug resistance (MDR) in Gram-negative bacteria has received a lot of attention recently, Gram-positive Antimicrobial resistance is also a serious concern [6]. MRSA (methicillin-resistant Staphylococcus aureus) is perhaps the most well-known example, and it is a major cause of community-acquired and healthcare-associated infection worldwide [7].

Vancomycin (VANC) and teicoplanin (TEIC) are glycopeptide antimicrobials that are only active against Gram-positive bacteria [6]. Since all glycopeptides currently available have low oral bioavailability, they must be administered parenterally for the treatment of systemic infections, typically by intravenous (IV) injection. TEIC and the newer lipophilic glycopeptidase are playing an increasingly important role in the delivery of OPAT [6].

Daptomycin, a cyclic lipopeptide, has a wide range of action against Gram-positive bacteria, including GRE and MRSA [8]. DAPT is a hydrophobic polypeptide with a lipophilic side chain that has 13 members [8]. This structure is thought to have a one-of-a-kind mechanism of action. The lipophilic area is thought to insert into the bacterial cell membrane, oligomerizing into pore-like structures and allowing substantial potassium ion efflux. Following membrane depolarization, DNA, RNA, and protein synthesis are immediately halted, resulting in rapid bacterial cell death.

The oxazolidinones (OXAs) are the most recent antimicrobial class to receive human approval. OXAs have bacteriostatic activity against a wide range of bacteria, mostly Gram-positive bacteria like MRSA and vancomycin-resistant enterococci (VRE). Cefazoline and ceftobiprole are fifth-generation Cephalosporins with a distinct bacteriological spectrum.

**EPIs Against Gram-Negative Bacteria Identified So Far**

The presence of lipophilicity and an additional outer membrane makes it impossible for amphipathic compounds to enter gram-negative bacteria. As a result, there are very few antibiotics that are specifically designed for gram-negative bacteria [9]. The proton motive force (PMF) drives the operation of Resistance-nodulation-division (RND) efflux pumps, which are proton antiporers. Antibiotic hybrids are a brand-new class of antimicrobials and adjuvants for Gram-negative pathogens. Aminoglycoside conjugates, for example, have been designed to deliver EPIs into cells. When used in combination with tetracycline, the EPIs 1-(1-naphthylmethyl)-piperazine and paroxetine conjugated to tobramycin decreased the electrical portion of the PMF, enhancing their adjuvant properties [10].

Further research revealed that when used against multidrug-resistant P. aeruginosa, tobramycin–EPI conjugates have a synergistic effect with fluoroquinolones, rifampicin, and Fosfomycin [10]. Blocking tripartite efflux pumps’ outer membrane factor (OMF) can also render them inactive [11]. The indole derivatives 3-amino-6-carboxyl-indolenin and 3-nitro-6-amino-indole have been shown to be able to block TolC, the OMF of various Enterobacteriaceae efflux pumps, increasing bacterial susceptibility to various antibiotics [12]. This group contains pyranopyridine derivatives. One of them, MBX2319, has broad antibacterial activity against E. coli and potentiates the antibacterial activity of a variety of AcrAB efflux pump substrates [13]. RND efflux pumps, in particular, use competitors that can bind to the efflux pump's substrate pocket, preventing other substrates from binding. These inhibitors have been shown to bind more closely to the AcrB binding pocket than antibiotic substrates, resulting in successful inhibition even at low concentrations [13]. The crystal structures of AcrB from E. coli and MexB from P. aeruginosa bound to the pyridopyrimidine derivative D13–D900 has recently been released, revealing the structural basis for RND transporter inhibition [13].

**OVERVIEW OF RECENT UPDATED COMPUTATIONAL TOOLS FOR EFFLUX PUMPS AND THEIR INHIBITORS**

The structural aspects of Multidrug resistant (MDR) pumps have been greatly enhanced by crystallographic structures, but this is insufficient to help structure-based drug design [14]. Computational methods, which can detect functional dynamics of biological systems, are a great resource for addressing mechanistic knowledge gaps.

Molecular docking, in particular, is useful in the silico method for identifying drug-binding sites, and Molecular dynamics (MD) simulations are comparable [14]. Becoming popular computational methods for both rationalizing existing data and making numerous predictions, such as drug recognition and binding, interaction-free energies, and translocation mechanism [14]. They are often used to verify homology models [14]. Furthermore, normal mode and functional mode analysis of protein movements allow for comparison of simulations of the apo and hollo structures, potentially leading to the discovery of factors closely linked to the efflux mechanism's first steps. Significant conformational changes that would usually be inaccessible by standard MD techniques due to large free energy barriers between such conformations and correspondingly unaffordable computational time have recently been sampled using 'coarse-grained simulations, in which generally four atoms are fused into one particle, and biased MD simulations [15]. Various computational studies on the EPIs of MDR pumps, predominantly RND and ATP-binding cassette (ABC)
transporters, have focused on identifying successful EPIs through high-throughput screening of compound databases and determining the mechanism of inhibition by inspecting molecular level inhibitor–pump interactions and coupled conformational changes in the transporters [16].

Although there has only been one published structure of an RND protein bound to an inhibitor, docking and molecular simulation studies were used to investigate the putative binding modes of other inhibitors such as PAN and N-Methylpyrrolidone (NMP), and in silico screening provided information on the binding of putative EPIs [5].

Table 1: Plant-derived EPIs with their structure, antibiotics, and complex efflux pumps.

<table>
<thead>
<tr>
<th>Bacteria</th>
<th>EPI</th>
<th>Efflux Pump</th>
<th>Antibiotic</th>
<th>Plant Source</th>
<th>Structure</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bacillus subtilis</td>
<td>Reserpine</td>
<td>Bmr</td>
<td>Tetracycline</td>
<td>Rauwolfia vomitoria</td>
<td><img src="image" alt="Reserpine structure" /></td>
<td>[17]</td>
</tr>
<tr>
<td>Bacillus cereus</td>
<td>Chalcone</td>
<td>NorA</td>
<td>Berberine, erythromycin and tetracycline</td>
<td>Nicotiana tobacum, Dalea versicolor</td>
<td><img src="image" alt="Chalcone structure" /></td>
<td>[18]</td>
</tr>
<tr>
<td>Streptococcus pneumoniae</td>
<td>Reserpine</td>
<td>NorA</td>
<td>Ciprofloxacin</td>
<td>Rauwolfia vomitoria</td>
<td><img src="image" alt="Reserpine structure" /></td>
<td>[17]</td>
</tr>
<tr>
<td>Staphylococcus aureus</td>
<td>Reserpine</td>
<td>TetK, NorA</td>
<td>Norfloxacin, Tetracycline</td>
<td>Rauwolfia vomitoria</td>
<td><img src="image" alt="Reserpine structure" /></td>
<td>[17]</td>
</tr>
<tr>
<td>Staphylococcus aureus</td>
<td>Carnosic acid &amp; Carnosol</td>
<td>Tet (K) &amp; Msr (A)</td>
<td>Tetracycline and erythromycin</td>
<td>Rosmarius officinalis</td>
<td><img src="image" alt="Carnosic acid structure" /></td>
<td>[19]</td>
</tr>
<tr>
<td>Staphylococcus aureus</td>
<td>Chalcone</td>
<td>NorA</td>
<td>berberine, erythromycin and tetracycline</td>
<td>Dalea versicolor</td>
<td><img src="image" alt="Chalcone structure" /></td>
<td>[20]</td>
</tr>
<tr>
<td>Bacteria</td>
<td>EPI</td>
<td>Efflux Pump</td>
<td>Antibiotic</td>
<td>Plant Source</td>
<td>Structure</td>
<td>References</td>
</tr>
<tr>
<td>------------------------</td>
<td>----------------------</td>
<td>-------------------</td>
<td>--------------------</td>
<td>-------------------</td>
<td>------------------------------------------------</td>
<td>------------</td>
</tr>
<tr>
<td><em>Staphylococcus aureus</em></td>
<td>Epicatech in gallate &amp; Epigallocatechin gallate</td>
<td>NorA</td>
<td>Norfloxacin</td>
<td><em>Camellia sinensis</em></td>
<td><img src="image1.png" alt="Structure" /></td>
<td>[21]</td>
</tr>
<tr>
<td><em>Staphylococcus aureus</em></td>
<td>Orizabin</td>
<td>Nor A</td>
<td>Norfloxacin</td>
<td><em>Ipomoea violacea</em></td>
<td><img src="image2.png" alt="Structure" /></td>
<td>[22]</td>
</tr>
<tr>
<td><em>Staphylococcus aureus</em></td>
<td>Piperine</td>
<td>MdeA &amp; Nor A</td>
<td>Ciprofloxacin</td>
<td><em>Piper nigrum, Piper longum</em></td>
<td><img src="image3.png" alt="Structure" /></td>
<td>[23]</td>
</tr>
<tr>
<td><em>Staphylococcus aureus</em></td>
<td>Salicylic acid</td>
<td>SarA</td>
<td>Ciprofloxacin, Ethidium bromide</td>
<td><em>Salix alba</em></td>
<td><img src="image4.png" alt="Structure" /></td>
<td>[24]</td>
</tr>
<tr>
<td><em>Staphylococcus aureus</em></td>
<td>Balsaminol, Balsaminagenin, Karavilagenin</td>
<td>NorA</td>
<td>AcrAB-TolC</td>
<td><em>Momordica balsamnia</em></td>
<td><img src="image5.png" alt="Structure" /></td>
<td>[22]</td>
</tr>
<tr>
<td><em>Staphylococcus aureus</em></td>
<td>Murucoids</td>
<td>Nor A</td>
<td>Norfloxacin</td>
<td><em>Ipomoea murucoides</em></td>
<td><img src="image6.png" alt="Structure" /></td>
<td>[12]</td>
</tr>
<tr>
<td><em>Staphylococcus aureus</em></td>
<td>Kaempferol Glycoside, Tiliroside</td>
<td>Nor A</td>
<td>Ciprofloxacin</td>
<td><em>Herissantia tiubae</em></td>
<td><img src="image7.png" alt="Structure" /></td>
<td>[25]</td>
</tr>
<tr>
<td><strong>Bacteria</strong></td>
<td><strong>EPI</strong></td>
<td><strong>Efflux Pump</strong></td>
<td><strong>Antibiotic</strong></td>
<td><strong>Plant Source</strong></td>
<td><strong>Structure</strong></td>
<td><strong>References</strong></td>
</tr>
<tr>
<td>-----------</td>
<td>--------</td>
<td>----------------</td>
<td>---------------</td>
<td>-----------------</td>
<td>--------------</td>
<td>---------------</td>
</tr>
<tr>
<td>Staphylococcus aureus</td>
<td>Ferrugino I</td>
<td>NorA</td>
<td>Norfloxacin, oxacillin</td>
<td>Chamaecyparis lawsoniana</td>
<td><img src="image1" alt="Structure" /></td>
<td>[26]</td>
</tr>
<tr>
<td>Staphylococcus aureus</td>
<td>Chalcone</td>
<td>Nor A</td>
<td>Ethidium bromide</td>
<td>Nicotiana tobacum</td>
<td><img src="image2" alt="Structure" /></td>
<td>[20]</td>
</tr>
<tr>
<td>Staphylococcus aureus</td>
<td>Pterocarp an</td>
<td>Nor A</td>
<td>Berberine</td>
<td>Dalea spinosa</td>
<td><img src="image3" alt="Structure" /></td>
<td>[27]</td>
</tr>
<tr>
<td>Staphylococcus epidermidis</td>
<td>Epigallocatechin Gallate</td>
<td>Tet(K)</td>
<td>Tetracycline</td>
<td>Camellia sinensis</td>
<td><img src="image4" alt="Structure" /></td>
<td>[28]</td>
</tr>
<tr>
<td>Mycobacterium spp.</td>
<td>Piperine</td>
<td>Rv125 8c</td>
<td>Ethidium bromide</td>
<td>Piper nigrum, Piper longum</td>
<td><img src="image5" alt="Structure" /></td>
<td>[29]</td>
</tr>
<tr>
<td>Enterococcus faecalis</td>
<td>Caaffeoyl quinic acid</td>
<td>NorA</td>
<td>Berberine</td>
<td>Artemisia absinthium</td>
<td><img src="image6" alt="Structure" /></td>
<td>[4]</td>
</tr>
<tr>
<td>E. coli</td>
<td>Baicalein</td>
<td>Tet K</td>
<td>Tetracycline</td>
<td>Thymus vulgaris</td>
<td><img src="image7" alt="Structure" /></td>
<td>[30]</td>
</tr>
<tr>
<td>EPI</td>
<td>Efflux pump</td>
<td>Antibiotic</td>
<td>Synthetic Source</td>
<td>Structure</td>
<td>References</td>
<td></td>
</tr>
<tr>
<td>------------------------------</td>
<td>------------------------------------------------------------------------------</td>
<td>---------------------------</td>
<td>------------------</td>
<td>-----------</td>
<td>------------</td>
<td></td>
</tr>
<tr>
<td>5,9-dimethyl-deca-2,4,8-trienoic acid amides</td>
<td>EPI against <em>Staphylococcus aureus</em></td>
<td>ciprofloxacin</td>
<td>Amide derivatives</td>
<td><img src="image1" alt="Structure" /></td>
<td>[31]</td>
<td></td>
</tr>
<tr>
<td>3-amino-6-carboxyl-indole</td>
<td>EPI against <em>E. coli</em> YD2 and FJ307 overexpressing AcrAB-TolC efflux pump</td>
<td>chloramphenicol, tetracycline, erythromycin and ciprofloxacin</td>
<td>Indole derivatives</td>
<td><img src="image2" alt="Structure" /></td>
<td>[32]</td>
<td></td>
</tr>
<tr>
<td>PAβN</td>
<td>RND efflux pumps (MexAB-OprM, MexCD-OprJ, MexEF-OprN, and MexXY-OprM).</td>
<td>chloramphenicol and macrolides</td>
<td>Valinomycin &amp; Dinitrophenol (DNP)</td>
<td><img src="image3" alt="Structure" /></td>
<td>[33]</td>
<td></td>
</tr>
<tr>
<td>Verapamil</td>
<td>EPI against <em>Mycobacterium tuberculosis</em> AND EPI of LmrA efflux pump of <em>Lactococcus lactis</em></td>
<td>isoniazid, rifampin and pyrazinamide</td>
<td>Verapamil</td>
<td><img src="image4" alt="Structure" /></td>
<td>[34]</td>
<td></td>
</tr>
<tr>
<td>CCCP</td>
<td>MFS efflux pump in <em>Mycobacterium smegmatis</em> 33 and in <em>Mycobacterium fortuitum</em></td>
<td>Carbapenem</td>
<td>Carbonyl cyanide m-chlorophenylhydrazone (CCCP)</td>
<td><img src="image5" alt="Structure" /></td>
<td>[35]</td>
<td></td>
</tr>
</tbody>
</table>
Sodium ortho-orthovanadate (Na3VO4) | ABC efflux pumps of *Streptococcus pneumoniae* | Ciprofloxacin & Ethidium bromide. | Sodium ortho-orthovanadate (Na3VO4) | [36]  

| 2,8-Dimethyl-4-(2'-pyrrolidinoethyloxyquinoline |  

| Efflux pumps in *E. aerogenes* and *K. pneumoniae* | Chloramphenicol, norfloxacin, tetracycline and cefepime | Alkoxynaphthoquinoline derivatives | Various alkoxy quinolines | [37]  

| Thiophene | NorA efflux pump of *Staphylococcus aureus* | Ciprofloxacin | Thiophene | [38]  

**FUTURE PERSPECTIVE**

Efflux pump inhibitors have so far been discovered by screening synthetic chemical agents or plant metabolites at random [39]. Researchers can classify the pharmacophores of a putative inhibitor that know the unique binding site of an efflux pump using advanced 3D structure resolution, molecular modeling, and molecular dynamics simulation. The ability of inhibitors to cross the outer membrane barrier is important in Gram-negative bacteria. Combining noncompetitive and competitive inhibitors and/or selective blockers to saturate the biological transport pathway is one way to achieve optimum pump inhibition. MDR transporters indicate that by manipulating molecular interactions that differentiate substrate transport from inhibitor binding, it may be possible to create inhibitors that can substantially and directly reduce efflux in bacteria [40]. Recent structures will certainly increase the chances of predicting a compound's export susceptibility, and this can be supplemented by using quantitative structure-activity relationship data to establish medicinal chemistry programs. These molecular docking studies aim to gain insight into the drug-protein interactions that differentiate between compounds [41]. The ability of computational biology to examine substrate recognition has been demonstrated; a combination of MD simulations and docking experiments offered a physicochemical explanation for the observed differences in the transport of various antibiotics or other drugs [42]. One of the most difficult aspects of developing EPIs for Gram-negative bacteria is creating compounds that can cross the outer membrane (OM) and bind to the RND pumps with high affinity [5]. These developments could help solve some of the major obstacles in the discovery and production of clinically beneficial EPIs when taken together.

**I. CONCLUSION**

In the last two decades, EPIs has become a popular research subject. A very few EPI is available till now for the treatment of Gram-negative infections due to their low stability, selectivity, and high cytotoxicity for eukaryotic cells. The interactions between antibacterial compounds and efflux pumps are complicated, making the development of successful EPIs difficult [43]. Since porins regulate the outer membrane's penetration, which favors zwitterionic and smaller hydrophilic molecules, developing novel EPIs in Gram-negative bacteria remains a difficult job. The main RND efflux pumps, on the other hand, prefer larger hydrophobic molecules. In this case, a logical design in which charged groups are attached where they will increase bacterial penetration can be used to identify a suitable location on EPIs. Nonetheless, the synthesis of these compounds will increase antibiotic resistance (including some antibiotics for which Gram-negative bacteria are intrinsically resistant) and, possibly for some particular efflux pumps, will reduce bacterial pathogen virulence [44].
ACKNOWLEDGMENT

The authors would like to thank their parents for assistance in some aspects of their study and for proofreading. They would also to thank anonymous reviewers for their suggestions that greatly helped in improving the quality of the paper.

REFERENCES

[31]. Niranjan Thota, Surrenderi Koul, et al. Citral derived amides as potent bacterial NorA efflux pump inhibitors. 2008 Jul 1